Glucose Transporter-1 As an Independent Prognostic Marker for Cancer: a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Feb 9

PMID 29416806

Citations 12

Authors

Zheng-Xiao Zhao

Lin-Wei Lu

Jian Qiu

Qiu-Ping Li

Fei Xu

Bao-Jun Liu

Jing-Cheng Dong

Wei-Yi Gong

Affiliations

Soon will be listed here.

Abstract

Objective: Glucose transporter-1 (GLUT-1) as the major glucose transporter present in human cells is found overexpressed in a proportion of human malignancies. This meta-analysis is attempted to assess the prognostic significance of GLUT-1 for survival in various cancers.

Materials And Methods: We conducted an electronic search using the databases PubMed, Embase and Web of Science, from inception to Oct 20th, 2016. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.

Results: Fourty-one studies with a total of 4794 patients were included. High GLUT-1 expression was significantly associated with poorer prognosis [overall survival: HR = 1.833 (95% CI: 1.597-2.069, < 0.0001); disease-free survival: HR = 1.838 (95% CI: 1.264-2.673, < 0.0001); progression-free survival: HR = 2.451 (95% CI: 1.668-3.233, < 0.0001); disease specific survival: HR = 1.96 (95% CI: 1.05-2.871, < 0.0001)].

Conclusions: High GLUT-1 expression may be an independent prognostic marker to predict poor survival in various types of cancers. Further clinical trials with high quality need to be conducted to confirm our conclusion.

Citing Articles

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours.

Bigos K, Quiles C, Lunj S, Smith D, Krause M, Troost E Front Oncol. 2024; 14:1331355.

PMID: 38352889 PMC: 10861654. DOI: 10.3389/fonc.2024.1331355.

Nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy based on NADPH depletion.

Zhang C, Liu Z, Wang F, Zhang B, Zhang X, Guo P Drug Deliv. 2022; 30(1):2162160.

PMID: 36579634 PMC: 9809347. DOI: 10.1080/10717544.2022.2162160.

Glucose transporters as markers of diagnosis and prognosis in cancer diseases.

Szablewski L Oncol Rev. 2022; 16(1):561.

PMID: 35340885 PMC: 8941341. DOI: 10.4081/oncol.2022.561.

Contemporary Perspectives on the Warburg Effect Inhibition in Cancer Therapy.

Kozal K, Jozwiak P, Krzeslak A Cancer Control. 2021; 28:10732748211041243.

PMID: 34554006 PMC: 8474311. DOI: 10.1177/10732748211041243.

Diagnostic potential of hypoxia-induced genes in liquid biopsies of breast cancer patients.

Peiro C, Perez M, de Aquino G, Encinas J, Sousa L, da Veiga G Sci Rep. 2021; 11(1):8724.

PMID: 33888756 PMC: 8062492. DOI: 10.1038/s41598-021-87897-2.

References

Ramani P, Headford A, May M . GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 2013; 462(2):203-9. DOI: 10.1007/s00428-012-1370-4. View

Eckert A, Lautner M, Schutze A, Taubert H, Schubert J, Bilkenroth U . Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology. 2011; 58(7):1136-47. DOI: 10.1111/j.1365-2559.2011.03806.x. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund L . Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer. 2010; 72(3):294-302. DOI: 10.1016/j.lungcan.2010.10.006. View

Hussein Y, Bandyopadhyay S, Semaan A, Ahmed Q, Albashiti B, Jazaerly T . Glut-1 Expression Correlates with Basal-like Breast Cancer. Transl Oncol. 2011; 4(6):321-7. PMC: 3243654. DOI: 10.1593/tlo.11256. View

Mayer A, Hockel M, Horn L, Schmidberger H, Vaupel P . GLUT-1 staining of squamous cell carcinomas of the uterine cervix identifies a novel element of invasion. Int J Oncol. 2010; 38(1):145-50. View

Kang S, Chun Y, Hur M, Lee H, Kim Y, Hong S . Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002; 93(10):1123-8. PMC: 5926879. DOI: 10.1111/j.1349-7006.2002.tb01214.x. View

Legan M, Luzar B, Marolt V . Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol. 2009; 44(9):1101-8. DOI: 10.1080/00365520903121685. View

10.

Shim B, Jung J, Lee K, Kim H, Hong S, Kim S . Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2012; 28(3):375-83. DOI: 10.1007/s00384-012-1542-3. View

11.

Younes M, Juarez D, Lechago L, Lerner S . Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001; 21(1B):575-8. View

12.

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

13.

Barron C, Bilan P, Tsakiridis T, Tsiani E . Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016; 65(2):124-39. DOI: 10.1016/j.metabol.2015.10.007. View

14.

Kim S, Jung W, Koo J . The Expression of Glut-1, CAIX, and MCT4 in Mucinous Carcinoma. J Breast Cancer. 2013; 16(2):146-51. PMC: 3706858. DOI: 10.4048/jbc.2013.16.2.146. View

15.

Eckert A, Lautner M, Taubert H, Schubert J, Bilkenroth U . Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep. 2008; 20(6):1381-5. View

16.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

17.

Haber R, Rathan A, Weiser K, Pritsker A, Itzkowitz S, Bodian C . GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40. DOI: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e. View

18.

Li C, Sun J, Gong Z, Lin Z, Liu H . Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis. Medicine (Baltimore). 2016; 95(45):e5324. PMC: 5106058. DOI: 10.1097/MD.0000000000005324. View

19.

Kim Y, Park Y, Yoon T, Lee S . Expression of the GLUT1 glucose transporter in gallbladder carcinomas. Hepatogastroenterology. 2002; 49(46):907-11. View

20.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View